| 前收市價 | 2.6300 |
| 開市 | 2.7700 |
| 買盤 | 2.6700 |
| 賣出價 | 2.9100 |
| 拍板 | 55.00 |
| 到期日 | 2025-05-16 |
| 今日波幅 | 2.7600 - 3.0500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 628 |
Motley Fool3 Surprisingly Underrated Stocks to Buy Right Now
These stocks might look like bad picks. But appearances can be deceiving.
Barrons.comThese Stocks Moved the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at Costco misses analysts’ estimates, and EchoStar rises on reports its Dish subsidiary is in merger talks with DirecTV.
BenzingaAbsence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares. The analyst notes that given that many prior antipsychotic medications received black box warnings due to increased mortality risks, particularly in elderly patients, Cobenfy’s absence of such a warning could
